Cargando…
Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study
The aim of this study was to investigate the efficacy and safety of chemoradiation using capecitabine and irinotecan as neoadjuvant therapy for patients with rectal cancer. Conventional radiation was given at daily fractions of 1.8 Gy on 5 days a week for a total dose of 55.8 (50.4+5.4) Gy. Concurre...
Autores principales: | Klautke, G, Küchenmeister, U, Foitzik, T, Ludwig, K, Prall, F, Klar, E, Fietkau, R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361227/ https://www.ncbi.nlm.nih.gov/pubmed/16552435 http://dx.doi.org/10.1038/sj.bjc.6603053 |
Ejemplares similares
-
Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer
por: Klautke, G, et al.
Publicado: (2005) -
Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2)
por: Gollins, S W, et al.
Publicado: (2009) -
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations
por: Gollins, Simon, et al.
Publicado: (2017) -
Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications
por: Schiffmann, Leif, et al.
Publicado: (2013) -
Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis
por: Schiffmann, Leif, et al.
Publicado: (2013)